Immune cell therapy shows promise for tough leukemia
NCT ID NCT04347616
First seen Apr 22, 2026 · Last updated May 14, 2026 · Updated 4 times
Summary
This study tested a new treatment for adults with acute myeloid leukemia (AML) that had come back or not responded to standard therapy. It used donated natural killer (NK) cells, a type of immune cell, given by infusion along with a drug called IL-2 to boost their activity. The goal was to see if this combination could safely reduce leukemia cells in the bone marrow. The study was stopped early, but it aimed to control the disease rather than cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA REFRACTORY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Radboud University Medical Center
Nijmegen, Netherlands
Conditions
Explore the condition pages connected to this study.